Efficacy of Pilsicainide After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
About this trial
This is an interventional treatment trial for Paroxysmal Atrial Fibrillation focused on measuring pilsicainide, class IC antiarrhythmic drug, paroxysmal atrial fibrillation, catheter ablation
Eligibility Criteria
Inclusion Criteria:
- patients with drug-refractory paroxysmal atrial fibrillation who requires catheter ablation
- patients who are aged 18-80 and agree with this study
Exclusion Criteria:
- patients who do not agree with this study
- patients with a history of catheter ablatio or surgery for atrial fibrillation
- patients who experienced side effects of pilsicainide before
- patients who has galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- patients who has congestive heart failure with ejection fraction<40% or decompensated heart failure
- patients with significant coronary artery disease, liver/renal disease
- patients who has other kinds of arrhythmic which requires active treatment
- contraindication to warfarin therapy
- life expectancy <1 year]
- pregnancy
Sites / Locations
- Arrhythmia center, Anam Hospital, Korea UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
pilsicainide
other class IC antiarrhythmic drug
The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.